HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

BFLY

Butterfly Network, Inc. (NYSE)

Healthcare — Medical Devices

Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; Butterfly Move, merging the mobility of a handheld with the stability of a full cart system; and iQ+ Bladder, a specialty product for bladder scanning market. It also provides Compass AI which offers one system to connect every device, workflow, and department; ScanLab, an AI-powered educational platform that provides written walkthroughs and reference imagery to guide real-time educational scanning; and Butterfly iQ+/iQ3 Vet, a third generation handheld ultrasound system. It sells and markets its products through a direct sales force, distributors, and e-commerce channels. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.

Strong Buy 1.0 / 5 4 analysts
$7.93
$-0.49 (-5.82%)
Target: $7.06 (-10.9%)
Sign in to add BFLY to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$2.07B
P/E Ratio (TTM)-
Forward P/E-85.73
EPS (TTM)$-0.30
Dividend Yield-
Profit Margin-73.63%
Revenue Growth25.00%
ROE-35.17%
Debt/Equity10.33
Recommendation Strong Buy 1.0
Analyst Target$7.06
Analysts4
Indexes NYSE

Technical Indicators

RSI (14)65.8
Beta2.20
SMA 20-
SMA 40-
52-Week High$9.69
52-Week Low$1.32
50-Day Avg$5.41
200-Day Avg$3.81
Avg Volume$7.05M
Volume$7.98M

Performance Analysis

BULLISH

BFLY shows predominantly bullish signals based on its fundamentals and technicals.

+ Showing strength at 79% of its 52-week range.
+ RSI at 65.8 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ Strong revenue growth of 25.0% year-over-year.
- Operating at a loss with -73.6% margin.
+ Wall Street consensus is "Strong Buy" from 4 analysts.
- Average analyst target of $7.06 implies 10.9% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 12:59 UTC

Back to Screener Export Report